Your AI-Trained Oncology Knowledge Connection!
Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses emerging agents in relapsed/refractory multiple myeloma.
Sonali M. Smith, MD, Elwood V. Jensen Professor in Medicine, director, Lymphoma Program, University of Chicago Medicine, discusses brentuximab vedotin (Adcetris) in cutaneous T-cell lymphoma.
Steven M. Ansell, MD, PhD, discusses the efficacy of PD-L1 blockade in Hodgkin lymphoma, patient treatment that has encouraged him to look for deeper solutions, alternative drug combinations that appear to be making headway, and potential avenues of discovery for the future.
Sagar Lonial, MD, discusses optimal sequencing techniques for patients with relapsed/refractory myeloma.
United States’ versus European perspectives on bleomycin in chemotherapy combinations for advanced Hodgkin lymphoma, along with the value of interim positron emission tomography, were discussed at the 2018 Pan Pacific Lymphoma Conference.
Jacqueline D. Barrientos, MD, MS, discusses the current treatment landscape for CLL, highlights some of the biggest challenges for physicians, and gives her insight on how to move forward in the field.
Major advancements in immunotherapy are at the forefront of treatment for patients with acute lymphoblastic leukemia.
Sham Mailankody, MBBS, discusses current treatment options and shifting preferences, especially toward triplet combinations, as well as emerging immunotherapy treatment options in multiple myeloma.
Mark J. Roschewski, MD, staff clinician, associate research clinician, clinical director, Malignancies Branch of the Center for Cancer Research, National Cancer Institute, discusses dose-adjusted infused etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (Rituxan; DA-EPOCH-R) in adult patients with Burkitt lymphoma.
Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the antibody drug conjugate polatuzumab vedotin in lymphoma.
A retrospective study of patients with Hodgkin lymphoma found high rates of sequelae including pulmonary events and cardiovascular disease following frontline treatment with chemotherapy including bleomycin.
Steven M. Horwitz, MD, discusses the best strategy for the treatment of CD30-positive peripheral T-cell lymphomas.
Sarah Holstein, MD, PhD, discusses new approaches to induction therapy for patients with myeloma.
David G. Maloney, MD, PhD, professor of medicine, Division of Oncology, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses updates with CAR T-cell therapy in non-Hodgkin lymphoma.
Julie M. Vose, MD, MBA, professor, internal medicine, chief, Division of Oncology & Hematology, University of Nebraska Medical Center, discusses the importance of genomic analysis in patients with non-Hodgkin lymphoma.
Combinations of novel drugs in lymphomas have the potential to overcome resistance to therapy but come with sometimes unexpected adverse events that demand careful monitoring.
With promising data of brentuximab vedotin and inotuzumab ozogamicin leading the way, antibody-drug conjugates are beginning to make a greater impact on the lymphoma treatment landscape.
An effective lymphodepletion strategy is critical to success with chimeric antigen receptor T-cell therapy, but also the choice of patients and even the cells used for CAR T cell manufacturing should be made with care.
Javier A. Pinilla-Ibarz, MD, PhD senior member, Moffit Cancer Center, discusses the recent advances in chronic myeloid leukemia (CML). Pinilla-Ibarz says that he and colleagues do not expect much in the field after other recent advancements, but he is still surprised to see what is being concentrated on today.
Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses evidence supporting the use of a triplet regimen versus a doublet regimen in elderly and transplant ineligible patients with multiple myeloma.
With newer agents approved for patients with chronic lymphocytic leukemia, physicians are now challenged with how best to utilize them.
George F. Geils, Jr, MD, discussed the clinical efficacy and adverse event management techniques for pembrolizumab as a treatment for patients with classical Hodgkin lymphoma.
Chimeric antigen receptor T-cell therapies have quickly moved from early phase clinical trials to FDA approval for diffuse large B-cell lymphoma, with research now exploring ways to shift these agents earlier in the treatment paradigm.
Gabriela S. Hobbs, MD, discusses how discontinuing tyrosine kinase inhibitors will change the treatment landscape and other strategies for treating patients with chronic myeloid leukemia.
Jacqueline D. Barrientos, MD, MS, CLL Research and Treatment Program, Northwell Health Systems, discusses the current challenges oncologists are faced with in the field of chronic lymphocytic leukemia.
Alexander M. Lesokhin, MD, assistant attending, Department of Medicine and Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses some of the exciting advancements currently happening in the field of multiple myeloma.
Results from the regorafenib dose optimization study (ReDOS) presented at the 2018 World Congress on GI Cancer established that the strategy of escalating regorafenib from 80 mg to 160 mg per day was superior to starting at a dose of 160 mg per day.
TAS-102 (trifluridine/tipiracil; Lonsurf) continued to show consistent benefits and safety in a real-world treatment setting for patients with refractory metastatic colorectal cancer.
Eileen M. O’Reilly, MD, speaks to the progress being made with immune therapies in pancreatic cancer.
Eileen O'Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses the role of immunotherapy in the treatment of patients with pancreatic cancer.
